We further found that treating the primary CLL B cells with ibrutinib for 24 h in vitro also resulted in the depletion of nuclear NFATc1 (Supplementary Fig. 8B). The gene discussed is NFATC1; the disease is B-cell chronic lymphocytic leukemia.